Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

458 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Bortezomib plus dexamethasone can improve stem cell collection and overcome the need for additional chemotherapy before autologous transplant in patients with myeloma.
Corso A, Barbarano L, Mangiacavalli S, Spriano M, Alessandrino EP, Cafro AM, Pascutto C, Varettoni M, Bernasconi P, Grillo G, Carella AM, Montalbetti L, Lazzarino M, Morra E. Corso A, et al. Leuk Lymphoma. 2010 Feb;51(2):236-42. doi: 10.3109/10428190903452826. Leuk Lymphoma. 2010. PMID: 20001242 Clinical Trial.
Panobinostat in combination with bortezomib and dexamethasone as induction therapy in patients with multiple myeloma, candidates for autologous transplant.
Mangiacavalli S, Pochintesta L, Ravelli E, Baldini L, Ferretti VV, La Targia ML, Farina L, Cocito F, Cairoli R, Montefusco V, Corso A. Mangiacavalli S, et al. Among authors: corso a. Leuk Lymphoma. 2015 Jun;56(6):1901-2. doi: 10.3109/10428194.2014.979414. Epub 2015 Jan 14. Leuk Lymphoma. 2015. PMID: 25347423 Clinical Trial. No abstract available.
Central nervous system involvement by multiple myeloma: A multi-institutional retrospective study of 172 patients in daily clinical practice.
Jurczyszyn A, Grzasko N, Gozzetti A, Czepiel J, Cerase A, Hungria V, Crusoe E, Silva Dias AL, Vij R, Fiala MA, Caers J, Rasche L, Nooka AK, Lonial S, Vesole DH, Philip S, Gangatharan S, Druzd-Sitek A, Walewski J, Corso A, Cocito F, Vekemans MC, Atilla E, Beksac M, Leleu X, Davila J, Badros A, Aneja E, Abildgaard N, Kastritis E, Fantl D, Schutz N, Pika T, Butrym A, Olszewska-Szopa M, Usnarska-Zubkiewicz L, Usmani SZ, Nahi H, Chim CS, Shustik C, Madry K, Lentzsch S, Swiderska A, Helbig G, Guzicka-Kazimierczak R, Lendvai N, Waage A, Andersen KT, Murakami H, Zweegman S, Castillo JJ. Jurczyszyn A, et al. Among authors: corso a. Am J Hematol. 2016 Jun;91(6):575-80. doi: 10.1002/ajh.24351. Epub 2016 Apr 24. Am J Hematol. 2016. PMID: 26955792 Free PMC article.
Is re-challenge still an option as salvage therapy in multiple myeloma? The case of REal-life BOrtezomib re-Use as secoND treatment for relapsed patients exposed frontline to bortezomib-based therapies (the REBOUND Study).
Musto P, Simeon V, Cascavilla N, Falcone A, Petrucci MT, Cesini L, Di Raimondo F, Conticello C, Ria R, Catalano L, Salvatore D, Mastrullo L, Gagliardi A, Villani O, Pietrantuono G, D'Arena G, Mansueto G, Bringhen S, Genuardi M, Di Renzo N, Reddiconto G, Fragasso A, Caravita T, Scapicchio D, Marziano G, Boccadoro M, Mangiacavalli S, Corso A. Musto P, et al. Among authors: corso a. Ann Hematol. 2019 Feb;98(2):361-367. doi: 10.1007/s00277-018-3524-1. Epub 2018 Oct 23. Ann Hematol. 2019. PMID: 30353388
458 results